The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Naltrexone and Disulfiram in Patients with Alcohol Dependence and Comorbid Psychiatric Disorders
Abstract
Background Disulfiram and naltrexone are approved by the Food and Drug Administration (FDA) for the treatment of alcoholism, but these agents have not been rigorously evaluated in dually diagnosed individuals.Method Two-hundred and fifty-four patients with an Axis I psychiatric disorder and comorbid alcohol dependence were treated for 12 weeks in an outpatient medication study conducted at three Veterans Administration outpatient clinics. Randomization included assignment to one of four groups: 1) naltrexone alone; 2) placebo alone; 3) (open-label) disulfiram and (blinded) naltrexone; or 4) (open-label) disulfiram and (blinded) placebo. Medication compliance was evaluated using the Microelectric Events Monitoring System. Primary outcomes were measures of alcohol use. Secondary outcomes included psychiatric symptoms, alcohol craving, g-GGT levels and adverse events.Results There was a high rate of abstinence across groups. Subjects treated with an active medication had significantly more consecutive weeks of abstinence and less craving than those treated with placebo, but there were no significant group differences in other measures of alcohol consumption. There was no advantage of the combination of both medications.Conclusions These data suggest a modest advantage for the use of disulfiram and naltrexone for this group of dually diagnosed alcohol-dependent individuals but did not suggest an advantage in the combination.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the combined control groups, six participants reported serious adverse events requiring hospitalization from three studies [38], [39], [42].”
From Disulfiram Efficacy in the Treatment of Alcohol Dependence: A Meta-Analysis (2014) · cites this paper as [38]
Citations
Cites
The brief symptom inventory: an introductory report.
Derogatis, L. R., & Melisaratos, N. (1983) · Psychological Medicine · doi:10.1017/s0033291700048017 · Cited by 6,650
The Hopkins Symptom Checklist (HSCL): A self-report symptom inventory
Derogatis, L. R., Lipman, R. S., Rickels, K., Uhlenhuth, E. H., & Covi, L. (1974) · Behavioral Science · doi:10.1002/bs.3830190102 · Cited by 4,604
The Structured Clinical Interview for DSM-III-R (SCID): I: History, Rationale, and Description
Spitzer, R. L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820080032005 · Cited by 4,336
Sobell, L. C., & Sobell, M. B. (1992) · Measuring Alcohol Consumption · doi:10.1007/978-1-4612-0357-5_3 · Cited by 4,110
Naltrexone in the Treatment of Alcohol Dependence
Volpicelli, J. R. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110040006 · Cited by 1,828
Davis, H. S. (1966) · JAMA · doi:10.1001/jama.1966.03100200106038 · Cited by 1,719
Naltrexone and Coping Skills Therapy for Alcohol Dependence
O’Malley, S. S. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110045007 · Cited by 1,476
Anton, R. F., Moak, D. H., & Latham, P. K. (1995) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.1995.tb01475.x · Cited by 679
Naltrexone in the Treatment of Alcohol Dependence
Krystal, J. H., Cramer, J. A., Krol, W. F., Kirk, G. F., & Rosenheck, R. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011127 · Cited by 618
The Hopkins Symptom Checklist (HSCL)
Lipman, R. S., Covi, L., & Shapiro, A. K. (1979) · Journal of Affective Disorders · doi:10.1016/0165-0327(79)90021-1 · Cited by 559
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–179 of 179
Bogenschutz, M. P., Bhatt, S. R., Bohan, J., Foster, B., Romo, P., Wilcox, C. E., & Tonigan, J. S. (2016) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2016.1168430 · Cited by 11
Clark, A. E., Goodwin, S. R., Marks, R. M., Belcher, A. M., Heinlein, E., Bennett, M. E., & Roche, D. J. O. (2021) · Journal of Dual Diagnosis · doi:10.1080/15504263.2021.1965407 · Cited by 10
An open label study of quetiapine in patients with schizophrenia and alcohol disorders
Brunette, M. F., Dawson, R., O’Keefe, C. D., Buckley, P. F., & Green, A. I. (2009) · Mental Health and Substance Use · doi:10.1080/17523280903156073 · Cited by 10
Pharmacotherapy treatment of PTSD and comorbid disorders.
Kozarić‐Kovačić, D. (2009) · PubMed · Cited by 10
Apolipoprotein E gene polymorphism and previous alcohol withdrawal seizures
Wilhelm, J., von Ahsen, N., Hillemacher, T., Bayerlein, K., Frieling, H., Kornhuber, J., & Bleich, S. (2006) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.07.011 · Cited by 9
The pharmacotherapeutic management of comorbid bipolar disorder and alcohol use disorder
Grunze, H., & Soyka, M. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2083500 · Cited by 11
Bernardy, N. C., Hamblen, J. L., Friedman, M. J., & Kivlahan, D. R. (2011) · Journal of Dual Diagnosis · doi:10.1080/15504263.2011.620446 · Cited by 9
Contemporary framework for alcohol craving.
Vuković, O., Cvetić, T., Zebić, M., Marić, N. P., Britvić, D., Damjanović, A., & Jašović‐Gašić, M. (2008) · PubMed · Cited by 9
Pharmacotherapy of Alcohol Dependence: Improving Translation from the Bench to the Clinic
Little, H. J., McKinzie, D. L., Setnik, B., Shram, M. J., & Sellers, E. M. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373861-5.00025-4 · Cited by 9
Cloud point extraction of disulfiram for its HPLC-MS/MS determination in synthetic urine
Doroschuk, V. O., Grogul, A. B., Mandzyuk, Y. S., Makukha, O. G., & Grytsyk, N. O. (2016) · Chemical Papers · doi:10.1515/chempap-2016-0074 · Cited by 9
Pharmakologische Rückfallprävention bei Alkohol- und Tabakabhängigkeit
Diehl, A., & Mann, K. F. (2006) · Der Internist · doi:10.1007/s00108-006-1755-z · Cited by 8
Bruce, R. D., Smith-Rohrberg, D., & Altice, F. L. (2007) · Springer eBooks · doi:10.1007/978-0-387-71695-4_23 · Cited by 9
Adding Psychotherapy to the Naltrexone Treatment of Alcohol Use Disorder: Meta-analytic Review
Ahmed, R., Kotapati, V. P., Khan, A., Hussain, N., Hussain, M., Dar, S., Kumar, J., Begum, G., Esang, M., Brainch, N., et al. (2018) · Cureus · doi:10.7759/cureus.3107 · Cited by 7
Charpeaud, T., Geneste, J., Schmidt, J., Llorca, P., & Brousse, G. (2011) · Therapies · doi:10.2515/therapie/2011025 · Cited by 7
Sodium oxybate plus nalmefene for the treatment of alcohol use disorder: A case series
Caputo, F., Maremmani, A. G. I., Addolorato, G., Domenicali, M., Zoli, G., d’Amore, A., Maremmani, I., & Bernardi, M. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116629126 · Cited by 8
Psychotische Störungen und komorbide Suchterkrankungen
Gouzoulis‐Mayfrank, E. (2016) · Forensische Psychiatrie Psychologie Kriminologie · doi:10.1007/s11757-015-0352-1 · Cited by 7
The Comorbidity of Post-Traumatic-Stress Disorder (PTSD) and Substance Use Disorders
Brady, K. T., McCauley, J. L., & Back, S. E. (2014) · Springer eBooks · doi:10.1007/978-88-470-5322-9_92 · Cited by 6
Komorbidität von Psychose und Sucht
Gouzoulis‐Mayfrank, E. (2009) · Psychiatrie und Psychotherapie up2date · doi:10.1055/s-0029-1223431 · Cited by 6
Brunette, M. F., O’Keefe, C. D., Zimmet, S. V., Wojcik, J., Dawson, R., Brownell, E., & Green, A. I. (2008) · Journal of Dual Diagnosis · doi:10.1080/15504260802313816 · Cited by 6
Morice, C., Yammine, L., Yoon, J. S., Lane, S. D., Schmitz, J. M., Kosten, T. R., Garza, R. D. L., & Verrico, C. D. (2022) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110506 · Cited by 7
Highlights in opioid agonists and antagonists
Lauretti, G. R. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.4.613 · Cited by 6
Gouzoulis‐Mayfrank, E., & Walter, M. (2014) · Springer eBooks · doi:10.1007/978-3-642-45375-5_6 · Cited by 5
Disulfiram (Antabus ®) in der Suchtbehandlung
Olbrich, R., & Olbrich, R. (2007) · SUCHT - Zeitschrift für Wissenschaft und Praxis / Journal of Addiction Research and Practice · doi:10.1024/2007.02.02 · Cited by 5
O'Neil, M. E., Cheney, T. P., Hsu, F. C., Carlson, K. F., Hart, E. L., Holmes, R. S., Murphy, K. M., Graham, E., Cameron, D. C., Kahler, J., et al. (2020) · doi:10.23970/ahrqepccer235 · Cited by 6
Mandaji, J. V. G., Pedro, M. O. P., Leopoldo, K., Alemar, J. P., Torales, J. C., Ventriglio, A., & Castaldelli-Maia, J. M. (2025) · Brain Sciences · doi:10.3390/brainsci15060542 · Cited by 5
Michael addition drugs and cancer
Tew, K. D., Townsend, D. M., Zhang, L., Zhang, X., Ye, Z., & Zhang, J. (2025) · Advances in cancer research · doi:10.1016/bs.acr.2025.06.004 · Cited by 4
Schallenberg, M., Pilhatsch, M., Petzold, J., Vogel, D., Zimmermann, U. S., & Spreer, M. (2024) · Addiction Science & Clinical Practice · doi:10.1186/s13722-024-00522-1 · Cited by 4
Comorbid Anxiety and Alcohol or Substance Use Disorders: An Overview
Bartoli, F., Carretta, D., & Carrà, G. (2020) · Springer eBooks · doi:10.1007/978-3-030-36391-8_92 · Cited by 3
Rosenstand, N. J., Nielsen, A. S., Skøt, L., Anhøj, S. J., Nielsen, D. G., Højlund, M., & Mellentin, A. I. (2022) · Current Neuropharmacology · doi:10.2174/1570159x21666221229160300 · Cited by 3
Co-occurring Substance and Mental Health Disorders
Quinones, L., Edens, E. L., & Rosenheck, R. A. (2018) · Springer eBooks · doi:10.1007/978-1-4939-7438-2_20 · Cited by 3
Alharbi, F., & el‐Guebaly, N. (2012) · Addictive Disorders & Their Treatment · doi:10.1097/adt.0b013e318246f4af · Cited by 2
The Treatment of Co-Occurring Psychiatric and Substance Use Disorders: New Findings and Unmet Needs
Brady, K. T. (2026) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20260096 · Cited by 1
Clinical implications of alcohol-use disorders in schizophrenia
Smith, M. J., & Csernansky, J. G. (2012) · Neuropsychiatry · doi:10.2217/npy.12.21 · Cited by 1
Pharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans
Arias, A. J., Gelernter, J. E., Gueorguieva, R. V., Ralevski, E., & Petrakis, I. L. (2013) · American Journal on Addictions · doi:10.1111/j.1521-0391.2013.12102.x · Cited by 1
Self-citationDisulfiram for Alcohol and Other Drug Use
Kerfoot, K. E., & Petrakis, I. L. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-398338-1.00038-5 · Cited by 1
Self-citationCo-Occurring Mood and Substance Use Disorders
Nunes, E. V., Hasin, D. S., & Weiss, R. D. (2014) · Springer eBooks · doi:10.1007/978-88-470-5322-9_89 · Cited by 1
Quadruple pharmacotherapy for alcohol use disorder tolerable yet insufficient: a case report
Terasaki, D., Ellinwood, A., & White, D. (2024) · Substance Abuse Treatment Prevention and Policy · doi:10.1186/s13011-024-00599-6 · Cited by 1
Comorbid Anxiety and Alcohol or Substance Use Disorders: An Overview
Bartoli, F., Carretta, D., Clerici, M., & Carrà, G. (2014) · Springer eBooks · doi:10.1007/978-88-470-5322-9_91 · Cited by 1
Differenzielle pharmakologische Rückfallprophylaxe bei Alkoholabhängigkeit
Mutschler, J., & Kiefer, F. (2011) · Journal für Kardiologie (Krause & Pachernegg GmbH) · doi:10.5167/uzh-58343 · Cited by 1
Reply to Comments by Mr Martin and Dr Beresford
Suh, J. J., Gallis, T. L., Kampman, K. M., & Pettinati, H. M. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000280313.96613.72 · Cited by 1
Pharmacotherapeutic Effects of Opioid Antagonists in Alcohol-Abusing Patients with Schizophrenia
Petrakis, I. L. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-197-0_25 · Cited by 1
Self-citationStevens, A. K., Blanchard, B. E., Shi, M., & Littlefield, A. K. (2020) · Wiley eBooks · doi:10.1002/9781119057840.ch178 · Cited by 1
Using Neuroscience to Guide the Development of New Pharmacotherapies for Alcoholism
Krishnan‐Sarin, S., O’Malley, S. S., & Krystal, J. H. (2009)
Pharmacological Therapeutics for Relapse Reduction in Addictive Disorders
Merlo, L. J., Blumenthal, K. G., Campbell, K. M., Omli, M. R., & Gold, M. S. (2010) · Wiley eBooks · doi:10.1002/9780470710449.ch33
Aslan, A. A., Yalçın, Ö., Arıkan, Z., Kuruoğlu, A., Çoşar, B., & Konuk, N. (2013) · Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology · doi:10.5455/bcp.20120903122839
Berglund, M. (2007) · Lund University Publications (Lund University)
Medications for Comorbid Bipolar Disorder and Addiction
Brown, E. S. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-398338-1.00051-8
The new pharmacotherapies for alcohol dependence
Mason, B. J., & Jacobs, M. B. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511782107.021
Specialist treatment of drinking problems
Humphreys, K. N., & Lingford-Hughes, A. R. (2016) · Cambridge University Press eBooks · doi:10.1017/cbo9781316258057.014
Preuss, U. W., Wong, W. M., & Farren, C. K. (2014)
Interdictores en el tratamiento del alcoholismo. Una revisión crítica
García, S. S. G. (2014) · Repository of Digital Objects for Teaching Research and Culture (University of Valencia)
Nava, F. A., Manzato, G., Rosa, S., & Caputo, F. (2017) · MISSION · doi:10.3280/mis45-2016oa4613
OPIOID RECEPTOR AGONISTS AND ANTAGONISTS
Schug, S. (2010) · Elsevier eBooks · doi:10.1016/b978-0-444-53273-2.50004-3
The Relationship of Alcohol Dependence to Monoamine Oxidase A
Matthews, B. A. (2015) · TSpace (University of Toronto)
Komplexe Dynamik der Komorbidität Schizophrenie und Cannabiskonsum
Schnell, T. G. (2018) · Springer eBooks · doi:10.1007/978-3-662-45995-9_20-1
Disulfiram and Its Use in Special Populations
Sousa, A. D. (2019) · Springer eBooks · doi:10.1007/978-981-32-9876-7_6
Disulfiram in Comparison and Combination with Other Agents in the Management of Alcohol Dependence
Sousa, A. D. (2019) · Springer eBooks · doi:10.1007/978-981-32-9876-7_5
Hahn, L. A. (2017) · Adelaide Research & Scholarship (AR&S) (University of Adelaide)
Drugs to Treat Substance Use Disorders
Sinclair, J., & Peters, L. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623465.017
Treatment: Context and content
Humphreys, K. N., & Lingford-Hughes, A. R. (2016) · Cambridge University Press eBooks · doi:10.1017/cbo9781316258057.009
Pharmacotherapy of alcohol misuse, dependence and withdrawal
Kenna, G. A., Agath, K., & Swift, R. M. (2008) · Cambridge University Press eBooks · doi:10.1017/cbo9780511544392.016
Arakelyan, A., Kempkensteffen, J., & Verthein, U. (2021) · Suchttherapie · doi:10.1055/a-1494-4333
Comorbid Anxiety and Substance Use Disorders
Brady, K. T. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3375-0_20
(2006) · Kluwer Academic Publishers eBooks · doi:10.1007/0-387-25733-0_14
Current awareness in human psychopharmacology
(2005) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.639
(2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.01129-x
(2005) · Biological Psychiatry · doi:10.1016/s0006-3223(05)00453-1
(2005) · Biological Psychiatry · doi:10.1016/s0006-3223(05)00639-6
Opioid analgesics and narcotic antagonists
Ghodse, A. H., & Galea, S. (2008) · Side effects of drugs annual · doi:10.1016/s0378-6080(08)00008-1
Behandlung von riskantem, schädlichem und abhängigem Alkoholgebrauch
Kiefer, F., Hoffmann, S., Arens, J., Beutel, M., Bilke-Hentsch, O., Bischof, G., Bonnet, U., Bumb, J. M., Demmel, R., Diestelkamp, S., et al. (2022) · Springer eBooks · doi:10.1007/978-3-662-63677-0_3
Co-occurring Disorders: Mental Health and Alcohol Use
Romano, N., & Luba, R. R. (2024) · Psychiatry update · doi:10.1007/978-3-031-73553-0_3
Bipolar Affective Disorders and Alcohol Dependence: Comorbidity, Consequences, and Treatment
Preuss, U. W., Wong, J., & Farren, C. (2015) · Springer eBooks · doi:10.1007/978-3-642-45375-5_9
Kumar, S., Shanmugham, S., Tan, F. Y., Kong, A. H. Z. X., Foong, C. X., Chan, J. E., Antony, P. T., Smales, F. C., Ching, S. M., Vadakkechalil, H., et al. (2025) · European Journal of Clinical and Experimental Medicine · doi:10.15584/ejcem.2025.4.15
A Novel ALDH2 Inhibitor for the Treatment of Alcohol Use Disorder: Preclinical Findings
Marshall, R. D., Fowlie, A., & Sabouni, A. (2026) · Cells · doi:10.3390/cells15020123
Réévaluation de l'apport du nalméfène au traitement de l'alcoolodépendance
Palpacuer, C. (2018) · theses.fr (ABES) · doi:10.70675/aa77e495z482ez45b0z9aabz3b0862e3413e
Bounthavong, M., Lau, M. K., Popish, S. J., Gray, J., Chen, A., Graham, R., Jubran, N., Stout, M. P., Schultz, E., Kay, C. L., et al. (2026) · Addiction · doi:10.1111/add.70495
Development of combined encapsulated drug on the basis of naltrexone and disulfiram
Новіков, В. П., Zayarnyuk, N. L., Кричковська, А. М., Федорова, О. В., & Милянич, А. О. (2015) · Technology audit and production reserves · doi:10.15587/2312-8372.2015.40651
Metadata
- Authors
- Petrakis, I. L., Poling, J., Levinson, C., Nich, C., Carroll, K., & Rounsaville, B.
- Affiliations
- Yale University (US)
- Corresponding author
- Petrakis, Ismene L.
- Venue
- Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2005-05
- Volume
- 57
- Issue
- 10
- Pages
- 1128-1137
- ISSN
- 0006-3223 (ISSN-L)
- OpenAlex
- W1985702729
- Cited by
- 177
- References
- 42
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 4 · 2023: 1 · 2022: 4 · 2021: 3 · 2020: 11 · 2019: 7 · 2018: 6 · 2017: 8 · 2016: 10 · 2015: 6 · 2014: 14 · 2013: 12 · 2012: 13
- FWCI
- 9.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biological Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Drug Abuse (K05DA000457)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Clinical Neurology › Alcoholism and Thiamine Deficiency
- Keywords
- naltrexone, disulfiram, alcoholism, psychiatric comorbidity, veterans, alcohol craving, alcohol abstinence, combination pharmacotherapy, gamma-glutamyl transferase, medication adherence
- MeSH terms
- Alcohol Deterrents, Alcoholism, Mental Disorders, Disulfiram, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Naltrexone, Narcotic Antagonists, Psychiatric Status Rating Scales, Treatment Outcome, Diagnosis, Dual (Psychiatry)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review